Clinical Trials Browser

OTHER_GOV × Breast Neoplasms × famitinib × Clear all

NCT05176080 2024-12-17

Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer

Phase 1/2 Terminated

Breast Neoplasms